Methods and compositions for diagnosing and treating disorders involving angiogenesis

An isolated nucleic acid molecule comprising:

• a) a nucleic acid as shown in SEQ ID NO:
• 1;
• or
• b) a nucleic acid as shown in SEQ ID NO:
• 3.

An isolated polypeptide comprising an amino acid sequence of:

• a) SEQ ID NO:
• 2;
• or
• b) SEQ ID NO:
• 4.

An isolated fusion polypeptide comprising a fusion peptide and an amino acid sequence of:

• a) SEQ ID NO:
• 2;
• or
• b) SEQ ID NO:
• 4.

A method for identifying a compound which modulates expression of an endostatin sequence comprising:

• a) contacting a test compound to a cell that expresses an endostatin sequence;
• b) measuring a level of endostatin sequence expression in the cell;
• c) comparing the level of endostatin sequence expression in the cell in the presence of the test compound to a level of endostatin sequence expression in the cell in the absence of the test compound,
• wherein if the level of endostatin sequence expression in the cell in the presence of the test compound differs from the level of expression of the endostatin sequence in the cell in the absence of the test compound, a compound that modulates expression of an endostatin sequence is identified.

A method for identifying a compound which modulates activity of an endostatin sequence product comprising:

• a) contacting a test compound to a cell that expresses an endostatin sequence product;
• b) measuring a level of endostatin sequence product in the cell;
• c) comparing the level of endostatin sequence product activity in the cell in the presence of the test compound to a level of endostatin sequence product activity in the cell in the absence of the test compound,
• wherein if the level of endostatin sequence product activity in the cell in the presence of the test compound differs from the level of endostatin sequence product activity in the cell in the absence of the test compound, a compound that modulates activity of an endostatin sequence product is identified.